Virus-Like Particles (VLPs) isotype control Protein (HEK293)
Based on 1 Customer Validation
Virus-Like Particles (VLPs) isotype control Protein (HEK293) is an empty virus-like particle, self-assembled from viral envelope or capsid proteins, and serves as a VLP control. Virus-Like Particles (VLPs) isotype control Protein (HEK293) can be used as a control for products such as CD133/PROM1 Protein-VLP, Human (HEK293, His) (HY-P78732), and Claudin-3/CLDN3 Protein-VLP, Human (HEK293, His) (HY-P700472). For more information on controls for other VLP proteins, please refer to the specific protein description. Virus-Like Particles (VLPs) isotype control Protein (HEK293) is a recombinant Virus-Like Particles (VLPs) isotype control Protein expressed by HEK293.
- Species: Virus
- Source: HEK293
-
Storage:Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Technical Parameters
-
Product Properties
- Documentation
- References
- Help & FAQs
Biological Activity
Description
Virus-Like Particles (VLPs) isotype control Protein (HEK293) is an empty virus-like particle, self-assembled from viral envelope or capsid proteins, and serves as a VLP control. Virus-Like Particles (VLPs) isotype control Protein (HEK293) can be used as a control for products such as CD133/PROM1 Protein-VLP, Human (HEK293, His) (HY-P78732), and Claudin-3/CLDN3 Protein-VLP, Human (HEK293, His) (HY-P700472). For more information on controls for other VLP proteins, please refer to the specific protein description. Virus-Like Particles (VLPs) isotype control Protein (HEK293) is a recombinant Virus-Like Particles (VLPs) isotype control Protein expressed by HEK293[1][2].
Background
Virus-Like Particles (VLPs) isotype control protein is a dedicated blank control particle that does not contain target membrane antigens and is formed solely by the self-assembly of viral structural proteins. It has the same particle structure, assembly method, and expression system as functional enveloped virus-like particles (VLPs) displaying antigens, thus eliminating non-specific immune responses and non-specific antibody binding signals from the virus-like particle scaffold itself. Virus-Like Particles (VLPs) isotype control protein differs fundamentally from functional Virus-like particles (VLPs) loaded with exogenous target proteins. It contains only pure viral envelope/capsid structural proteins and does not carry any exogenous target membrane proteins, forming blank particles after assembly that do not contain the viral genome and have no infectivity. Virus-Like Particles (VLPs) isotype control protein serves as a negative control for experiments using Virus-like particles (VLPs) and is suitable for animal immunization, ELISA antibody binding detection, FACS cell experiments, and high-throughput antibody screening[1][2].
Technical Parameters
-
Species Virus
-
Source HEK293
-
Tag Tag Free
-
Accession
Sequence information is not available or disclosed for this product.
-
Gene ID/
-
Synonyms
/
-
Predicted Molecular Mass
56.1 kDa
-
Purity
/
Product Properties
Lyophilized powder.
Lyophilized from a 0.22 μm filtered solution of PBS, 6% trehalose, pH 7.4.
<1 EU/μg, determined by LAL method.
It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O.
Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Room temperature in continental US; may vary elsewhere.
Documentation
-
Data Sheet (260 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Nooraei S, et al. Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers. J Nanobiotechnology. 2021 Feb 25;19(1):59. [Content Brief]
[2]. Bachmann MF, et al. Virus-like particles: a versatile and effective vaccine platform. Expert Rev Vaccines. 2025 Dec;24(1):444-456. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz
